XRP0038 (NV1FGF)

Phase 1Small molecule

Sanofi

XRP0038 (NV1FGF) is one of 30 small molecule programs targeting Amputation. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AmputationActive, not recruiting

AmputationPhase 1

Active, not recruiting

Competition

Competitive Landscape

42 competitors in Amputation

#DrugCompanyPhaseTrials

Acanya

Pfizer

Approved

1 2

Peridex

DDexcel Pharma Technologies Ltd.

Approved

1 3

Ansaid

PPharmacia and Upjohn

Approved

1 4

Flagyl

DDePuy Orthopaedics

Approved

1 5

Teicoplanin

Sanofi

Approved

1 6

Liposomal Bupivacaine

TTLC Biopharmaceuticals, Inc.

Approved

2 7

Depakote

AbbVie

Phase 2

1 8

Iodine

UUniversity of California, Los Angeles

Approved

1 9

Co-Amoxiclav

IImperial College London

Approved

1 10

Xylocaine

MMEDRx USA, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy and Safety2 trials

Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.

Completed· Sanofi logo

Sanofi·Phase 2·NCT00798005·71 enrolled

Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease

Completed· Sanofi logo

Sanofi·Phase 2·NCT00368797·125 enrolled

ART1 trial

Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease

Completed· Sanofi logo

Sanofi·Phase 1·NCT01157156·51 enrolled

Intermittent Claudication1 trial

Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent Claudication

Completed· Sanofi logo

Sanofi·Phase 2·NCT01157871·36 enrolled

Amputation1 trial

Gene Expression and Tolerability Study of NV1FGF in Patients With Peripheral Artery Occlusive Disease Planned to Undergo Major Amputation

Completed· Sanofi logo

Sanofi·Phase 1·NCT01157143·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for XRP0038 (NV1FGF). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — XRP0038 (NV1FGF) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for XRP0038 (NV1FGF). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Sanofi

XRP0038 (NV1FGF)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Efficacy and Safety2 trials

ART1 trial

Intermittent Claudication1 trial

Amputation1 trial

References

Drug Info

Quick Facts

Related News